PMID-31625062 – Selank Protects Against Ethanol-Induced Memory Impairment
Kolik LG et al., "Selank Peptide Protects Against Ethanol-Induced Memory Impairment," Bull Exp Biol Med, 2019;167(5):670-673.
Quick Reference
| Property | Value |
|---|---|
| PMID | 31625062 |
| DOI | 10.1007/s10517-019-04588-9 |
| Year | 2019 |
| Journal | Bulletin of Experimental Biology and Medicine |
| Study Type | Animal in vivo |
| Evidence Level | V |
| Sample | Rats with chronic ethanol exposure (30 weeks, 10% ethanol) |
| Peptide(s) Studied | Selank |
Key Findings
- Selank (0.3 mg/kg/day for 7 days) prevented ethanol-induced memory and attention deficits in rats after 30 weeks of chronic 10% ethanol consumption
- Selank treatment normalized BDNF content in both the hippocampus and prefrontal cortex, regions critical for memory and executive function
- Cognitive-stimulating effects were also observed in aged control rats not exposed to ethanol, suggesting broader nootropic potential
Study Design
Rats were subjected to chronic ethanol consumption (10% ethanol solution) for 30 weeks to model alcohol-induced cognitive decline. Selank was administered at 0.3 mg/kg/day for 7 days, after which cognitive performance was assessed via memory and attention tasks. BDNF levels were measured in hippocampus and prefrontal cortex post-treatment.
Limitations
- Animal model — ethanol consumption paradigm and cognitive assessments may not directly translate to human alcohol use disorder
- Short treatment duration (7 days) limits understanding of sustained efficacy
- Single dose level tested; dose-response relationship not established
Clinical Relevance
These results suggest Selank may offer neuroprotective and cognitive-restorative benefits in the context of chronic alcohol exposure, with the BDNF normalization mechanism supporting its potential as a nootropic agent for age-related and substance-induced cognitive decline.
Related
#research #animal-in-vivo #evidence-level-V